seen from United States
seen from United States
seen from China
seen from United States
seen from China
seen from United States
seen from China
seen from Australia
seen from Yemen
seen from China
seen from China
seen from Russia
seen from United Kingdom
seen from United Kingdom
seen from Maldives
seen from Singapore
seen from United States
seen from Türkiye
seen from Italy
seen from China
BESPONSA (Mechanism of Action)
BESPONSA (Mechanism of Action)
In this article, we will discuss BESPONSA (Mechanism of Action). So, let’s get started. Mechanism of ActionInotuzumab ozogamicin is a CD22-directed antibody-drug conjugate (ADC). Inotuzumab recognizes human CD22. The small molecule, N-acetyl-gamma-calicheamicin, is a cytotoxic agent that is covalently attached to the antibody via a linker. Nonclinical data suggest that the anticancer activity of…
View On WordPress
BESPONSA and Hepatotoxicity
In this article, we will discuss BESPONSA and Hepatotoxicity. So, let’s get started. Hepatotoxicity, Including Hepatic Veno-occlusive Disease (VOD) (also known as Sinusoidal Obstruction Syndrome) Inform patients that liver problems, including severe, life-threatening, or fatal VOD, and increases in liver tests may develop during BESPONSA treatment. Inform patients that they should seek…
View On WordPress
BESPONSA and Myelosuppression
In this article, we will discuss BESPONSA and Myelosuppression. So, let’s get started. Myelosuppression Inform patients that decreased blood counts, which may be life-threatening, may develop during BESPONSA treatment and that complications associated with decreased blood counts may includeinfections, which may be life-threatening or fatal, and bleeding/hemorrhage events. Inform patients that…
View On WordPress
BESPONSA and Infusion Related Reactions
BESPONSA and Infusion Related Reactions
In this article, we will discuss BESPONSA and Infusion Related Reactions. So, let’s get started. Infusion Related Reactions In the INO-VATE ALL trial, infusion related reactions were observed in patients who received BESPONSA. Infusion related reactions (all Grade 2) were reported in 4/164 patients (2%). Infusion related reactions generally occurred in Cycle 1 shortly after the end of the…
View On WordPress
BESPONSA (Mechanism of Action)
BESPONSA (Mechanism of Action)
In this article, we will discuss BESPONSA (Mechanism of Action). So, let’s get started. Mechanism of ActionInotuzumab ozogamicin is a CD22-directed antibody-drug conjugate (ADC). Inotuzumab recognizes human CD22. The small molecule, N-acetyl-gamma-calicheamicin, is a cytotoxic agent that is covalently attached to the antibody via a linker. Nonclinical data suggest that the anticancer activity of…
View On WordPress
BESPONSA
In this article, we will discuss BESPONSA (Dosage Overview). So, let’s get started. IndicationsBESPONSA is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).DosageRecommended Dosage• Pre-medicate before each dose.• For the first cycle, the recommended total dose of BESPONSA for all patients is 1.8 mg/m² per cycle, administered…
View On WordPress
Top Pharma News of the Week
Top Pharma News of the Week
Repatha® (Evolocumab) Phase 3 Cognitive Function Study Results Published In The New England Journal Of Medicine
August 16, 2017
Amgen has announced that the New England Journal of Medicine (NEJM) published results from the Repatha® (evolocumab) cognitive function trial (EBBINGHAUS), which was conducted in a subset of patients enrolled in the randomized, placebo-controlled Repatha cardiovascular…
View On WordPress
Top Pharma News of the Week
Top Pharma News of the Week
Seattle Genetics gets a PhIII win for Adcetris
June 26, 2017
Seattle Genetics says that its flagship therapy, Adcetris, combined with a trio of standard drugs beat a 4-drug mainstay cocktail therapy in frontline Hodgkin disease for modified progression-free survival over a lengthy two-year stretch. The Adcetris package excluded bleomycin, which has been linked to a higher rate of lung toxicity…
View On WordPress
